科研之友
微信
新浪微博
Facebook
分享链接
摘要
Background: The aim of this study was to model the cost-effectiveness of carotid endarterectomy for asymptomatic stenosis versus medical therapy based on 10-year data from the Asymptomatic Carotid Surgery Trial (ACST). Methods: This was a costutility analysis based on clinical effectiveness data from the ACST with UK-specific costs and stroke outcomes. A Markov model was used to calculate the incremental cost-effectiveness ratio (ICER, or cost per additional quality-of-life year) for a strategy of early endarterectomy versus medical therapy for the average patient and published subgroups. An exploratory analysis considered contemporary event rates. Results: The ICER was pound 7584 per additional quality-adjusted life-year (QALY) for the average patient in the ACST. At thresholds of pound 20 000 and pound 30 000 there was a 74 and 84 per cent chance respectively of early endarterectomy being cost-effective. The ICER for men below 75 years of age was pound 3254, and that for men aged 75 years or above was 71 pound 699. For women aged under 75 years endarterectomy was less costly and more effective than medical therapy; for women aged 75 years or more endarterectomy was less effective and more costly than medical therapy. At contemporary perioperative event rates of 2.7 per cent and background any-territory stroke rates of 1.6 per cent, early endarterectomy remained cost-effective. Conclusion: In the ACST, early endarterectomy was predicted to be cost-effective in those below 75 years of age, using a threshold of pound 20 000 per QALY. If background any-territory stroke rates fell below 1 per cent per annum, early endarterectomy would cease to be cost-effective.
- 出版日期2013-1
